Latest news
Loading news…
Par'Immune
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 MediumHeat score — how much recent activity & attention the company has (web traffic, news, hiring). Marquette Lez Lille, Nord-Pas-de-Calais, France Founded 2017 251-500 employees For Profit
Par'Immune develops P28GST, a parasite-derived protein used as an immunotherapy to treat autoimmune conditions like Crohn's disease.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
0
Patents
1
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 10
- Patents granted
- 1
- Trademarks
- 0
- Top patent class
- a61
Company Info
- Founded
- 2017
- Employees
- 251-500
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 2
- HQ
- Marquette Lez Lille, Nord-Pas-de-Calais, France
- Region
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Signals & Scores
- Heat score
- Medium
- Trend (7d)
- 0
- Trend (30d)
- 0.7
- Trend (90d)
- -0.2
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Par'Immune
Loading news…
FAQs about Par'Immune
People who checked this page also checked these
Browse the full Acquirezy directory.